ELUT ELUTIA INC.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001708527
AI RATING
SELL
85% Confidence

Investment Thesis

Elutia exhibits severe operational dysfunction with massive operating losses (-218.9% margin) despite modest revenue of $12.3M, which declined 15% YoY. The extraordinary net income of $53.4M appears driven by non-operating gains (likely asset sales or accounting adjustments) rather than core business performance, masking deteriorating fundamentals. Negative free cash flow of -$46.7M combined with $26.1M long-term debt and rapidly depleting cash reserves signal an unsustainable burn rate.

Strengths

  • + Strong liquidity position with $36.4M cash and 2.22x current ratio provides near-term runway
  • + High gross margin of 53.7% indicates viable product economics at the unit level
  • + Moderate leverage ratio of 0.94x debt-to-equity provides some balance sheet cushion

Risks

  • ! Severe cash burn of $46.7M free cash flow with only 10+ quarters of runway at current burn rate
  • ! Revenue contraction of 15% YoY combined with -218.9% operating margin indicates business is not scaling profitably
  • ! Negative interest coverage of -20.5x indicates inability to service debt from operating earnings; dependent on non-recurring gains
  • ! Operating cash flow of -$44.8M signals core business is destroying rather than generating cash
  • ! Net margin of 434.2% is unrealistic and driven by one-time items, masking true operational performance

Key Metrics to Watch

Financial Metrics

Revenue
12.3M
Net Income
53.4M
EPS (Diluted)
$0.87
Free Cash Flow
-46.7M
Total Assets
62.4M
Cash
36.4M

Profitability Ratios

Gross Margin 53.7%
Operating Margin -218.9%
Net Margin 434.2%
ROE 192.9%
ROA 85.6%
FCF Margin -379.8%

Balance Sheet & Liquidity

Current Ratio
2.22x
Quick Ratio
2.12x
Debt/Equity
0.94x
Debt/Assets
55.6%
Interest Coverage
-20.50x
Long-term Debt
26.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-24T06:40:11.425230 | Data as of: 2025-12-31 | Powered by Claude AI